Kinidinesulfaat Teva

Quinidine sulfate, the active ingredient in Kinidinesulfaat Teva, is a Class I antiarrhythmic (Ia) presented as an oral dosage form for oral use. It is used to manage atrial fibrillation, atrial flutter and certain ventricular arrhythmias in adult patients. It belongs to the antiarrhythmic therapeutic class and works by modifying cardiac electrical activity. The drug is indicated for rhythm control in patients with supraventricular and ventricular tachyarrhythmias, and is administered under medical supervision. Therapeutic decisions are guided by electrocardiographic findings and patient-specific risk factors.

GNH USA supplies Kinidinesulfaat Teva as a licensed, GDP‑compliant supplier serving hospitals, pharmacies and clinics worldwide.

Quinidine sulfate is used to treat cardiac rhythm disorders by targeting abnormal electrical conduction.

Atrial fibrillation: restores sinus rhythm and reduces ventricular response. Atrial flutter: facilitates conversion to sinus rhythm. Ventricular arrhythmias: suppresses ectopic ventricular activity.

Quinidine sulfate may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting. - Dizziness or light‑headedness. - Headache. - Visual disturbances such as blurred vision. - Constipation. - Mild hypotension.

Serious or Rare Side Effects: - Severe hypotension or shock. - Worsening of arrhythmias, including torsades de pointes. - Thrombocytopenia or other blood dyscrasias. - Hepatic dysfunction or jaundice. - Severe allergic reactions (anaphylaxis, skin rash). - Prolonged QT interval leading to ventricular tachycardia.

When prescribing quinidine sulfate, clinicians should consider several safety measures.

Monitor ECG: regular ECGs to detect QT prolongation or new arrhythmias. Assess renal and hepatic function: adjust therapy if organ impairment is present. Avoid use in patients with known hypersensitivity to quinidine or related compounds. Use caution in patients with pre‑existing conduction disorders or bradycardia. Elderly patients may require closer monitoring due to increased sensitivity. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Quinidine sulfate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Co‑administration with other Class I antiarrhythmics may precipitate severe arrhythmias. - Macrolide antibiotics (e.g., erythromycin, clarithromycin) can increase quinidine plasma levels. - Digoxin may have enhanced toxicity when combined with quinidine.

Moderate Interactions (Monitor Closely): - Beta‑blockers may produce additive bradycardia. - Calcium channel blockers can augment negative inotropic effects. - Diuretics may alter electrolyte balance, affecting quinidine activity. - Certain antidepressants (e.g., SSRIs) may modestly raise quinidine concentrations.